← Eichor
Condition: Metastatic Pancreatic Ductal Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Pancreatic Ductal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 15 location(s) · SOFIE · NCT07217717A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Phase 2 · 13 location(s) · Belgian Group of Digestive Oncology · NCT05472259Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
NA · 7 location(s) · Institut Curie · NCT05475366Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT07214298CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06937567PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa
Phase N/A · 1 location(s) · Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di · NCT07252076Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxe
Phase 1/Phase 2 · 4 location(s) · Onconic Therapeutics Inc. · NCT05257993Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a
Phase 1/Phase 2 · 6 location(s) · Phanes Therapeutics · NCT05431270TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Phase 1/Phase 2 · 5 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT07284277A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2 · 1 location(s) · University of Miami · NCT07096362A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastati
Phase 1/Phase 2 · 1 location(s) · Theriva Biologics SL · NCT07701486Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pa
Phase 2 · 26 location(s) · Endevica Bio · NCT06937177Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · University of California, San Diego · NCT06790602Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/Phase 2 · 18 location(s) · Tango Therapeutics, Inc. · NCT06922591SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer
Phase N/A · 1 location(s) · Medical University of Vienna · NCT05752812
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.